Barón Saura J M, Pizarro Redondo A, Berrocal Jaime A, González Barón M
Servicio de Oncología Médica, Hospital La Paz, Madrid.
Rev Clin Esp. 1991 May;188(9):468-72.
Interleukin-2 (IL2), as a modifier of the biological response, has been intravenously used in patients with advanced cancer associated or not to LAK cells or tumor infiltrating lymphocytes. In different neoplasias positive results have been obtained, being effective in melanoma and renal cancer. There are still, at present, many questions to be answered and multiple research lines are currently open. The association with other cytokines and new chemotherapy protocols grant new therapeutic possibilities.
白细胞介素-2（IL2）作为一种生物反应调节剂，已被静脉注射用于患有或未伴有淋巴因子激活的杀伤细胞（LAK细胞）或肿瘤浸润淋巴细胞的晚期癌症患者。在不同的肿瘤中已取得了阳性结果，对黑色素瘤和肾癌有效。目前仍有许多问题有待解答，多条研究路线目前仍在进行。与其他细胞因子的联合使用以及新的化疗方案带来了新的治疗可能性。
